who should not take bpc 157 The Hidden Risks of BPC‑157: What Patients Need to Know About Contamination and Safety BPC-157 – Mark Hyman, MD

This product is intended exclusively for research, analytical, and educational applications

Hematologic and biochemical monitoring throughout the trials revealed no concerning patterns in blood counts, liver function tests, kidney function markers, or other laboratory parameters

But that doesnt mean other high-level physicians and biohackers have ignored its positive yet powerful effects on body recomposition

Why Metabolic Safety Matters Full-length human growth hormone therapy carries well-documented metabolic risks including IGF-1 elevation, impaired glucose tolerance, and increased diabetes risk

Peter Attia, a longevity physician, discusses NAD+ precursors: "While evidence is emerging, NAD+ boosting shows promise for mitochondrial health and longevity, though IV might not be optimalprecursors like NMN could be better."[33][20] On combinations, he cautions on long-term data but notes potential for metabolic disorders

They make sense conceptually but need clinical trials to determine safety, dosage, timing and interactions